Biomarkers and Case Reports


Vaccines prevent infectious diseases, but vaccination is not without risk and adverse events are reported although they are more commonly reported for biologicals than for vaccines. Vaccines and biologicals must undergo a rigorous assessment before and after licensure to minimize safety concerns. Potential safety concerns should be identified as early as possible during the development of vaccines and biologicals to minimize investment risk. State-of-the-art tools and methods to identify safety concerns and biomarkers that are predictive of clinical outcomes are indispensable. For vaccines and adjuvant formulations, systems biology approaches, supported by single-cell microfluidics applied to translational studies between preclinical and clinical studies, could improve reactogenicity and safety predictions.


    Related Conference of Biomarkers and Case Reports

    August 22-23, 2022

    4th World Congress on Vaccine and Immunology

    Toronto, Canada
    September 05-06, 2022

    42nd Global Summit and Expo on Vaccines & Immunology

    Paris, France
    November 04-05, 2022

    34th Annual Congress on Vaccine and Clinical Trials

    Toronto, Canada
    November 17-18, 2022

    2nd Global Summit on Vaccines and Immunology

    Berlin, Germany
    February 20-21, 2023

    International Conference on Vaccine Research

    Madrid, Spain

    Biomarkers and Case Reports Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in